Cancer occurs when cells begin to divide and reproduce abnormally. If unstopped, cancer will continue to grow and spread across the body (called metastasis). There are many types of cancer, and it can begin in almost any organ. Often, cancers will form large, solid masses of cancer cells called tumors. Multiple factors such as genetics, diet, and tobacco use can increase the risk of developing cancer, so researchers are working to better understand these effects. Early detection can make treatment more successful, and many researchers focus on ways to spot warning signs earlier. Because powerful treatments like chemotherapy and radiation are needed to defeat cancer, there is always a push to find new, effective treatments with minimal side effects.
MyPaTH Story Booth 2.0
Interested in sharing your story about health, illness, or research? Patients and caregivers are needed to participate in a research study to help learn more about topics that are important to you and that may improve health and health care. Participation involves one 45-minute session that takes place over the phone. Eligible participants must be able to read and understand English.
Patients with High-Grade Upper Tract Urothelial Cancer
Do you have high-grade upper tract urothelial cancer (UTUC)? You may be eligible for a research study to find out if the Durvalumab approach is better or worse than the usual approach for upper tract urothelial cancer.
Have you been diagnosed with Stage IV cancer? Do you have a smartphone? You may be able to participate in a study to define what quality of life looks like on a daily basis for people living with advanced cancer. Compensation is provided.
Sleep Intervention Study – Individuals with Cancer
Are you age 21 or older and diagnosed with cancer? You may be able to participate in a research study to test a treatment to improve sleep that includes you and your loved one and to see if it is more effective than treating sleep problems individually. This study involves engaging in a 1 hour session each week for 5-6 weeks. Your spouse/partner must be willing to participate in this study.
MyPaTH Story Booth – COVID-19 Stories
Participants are invited to share how they are maintaining their health during the coronavirus pandemic, or to share what it is like being ill with COVID-19 and/or caring for a loved one who is ill with COVID-19. Participation in this research study involves one 45-minute session that takes place over the phone. Eligible participants must be able to read and understand English.
Are you at least 65 years old? If so, you may be eligible to participate in a research study to determine if taking Equol, a plant-based supplement, could slow the progression of stiffening of the arteries, small blood vessel disease in the brain and memory decline. The ACE Trial is short for: Arterial Stiffness, Cognition and Equol.
Work Limitations in Nurses with Cancer
Are you a nurse that has been diagnosed with cancer? You may be eligible for a research study to understand work experiences among nurses with cancer.
Well-Being After Breast Cancer Surgery
Are you a breast cancer, DCIS, or LCIS survivor experiencing pain in the area of your breast surgery? You may be able to participate in a research study to compare three different informational programs to help you improve your long-term well-being after breast cancer surgery. Compensation is provided.
Neuroendocrine Tumors - Patient Reported Outcomes (NET-PRO)
Are you 18 or over with a gastroenteropancreatic (GEP) or lung neuroendocrine tumor (NET)? You may be eligible to participate in a research study based on your NET diagnosis. Compensation is provided.
All of Us Pennsylvania Research Program
You may be able to change the future of medicine. The All of Us PA Research Program is enrolling adults 18 years of age or older. This may be your chance to improve how your children and your children’s children receive medical care.
Squamous Cell Carcinoma of the Lower Extremities Study
Have you been diagnosed with squamous cell carcinoma (SCC) on your lower extremity (below the knee)? If so, you may be eligible to participate in a study to help researchers determine if the need for surgical treatment of SCC can be eliminated by injecting a solution of a chemotherapeutic drug.
Decentralized Biobanking "de-bi": An app for tracking research donations
Are you 18 and older and interested what happens to the tumor/tissue/blood you donate for research? This research project is developing an app for those who want to track or learn about their biosample donations and studying patient preferences for feedback about research on their biosamples.
Are you currently receiving chemo for cancer at UPMC? Do you have a smartphone? You may be able to participate in a study to monitor symptoms during chemotherapy using smartphones and Fitbits. Participation involves installing study apps on your smartphone and completing daily questionnaires for 90 days. Compensation is provided.
HCC 19-059 - ICONIC Study
Do you have a rare genitourinary (GU) tumor? If so, you may be eligible to participate in a study to help researchers test the good and bad effects of three combined cancer drugs, called cabozantinib, nivolumab, and ipilimumab, that are FDA-approved individually, but not in combination.
AtTACC Pain Study – Ovarian Cancer Survivors
Are you an ovarian cancer survivor? You may be able to participate in a study to help better understand how pain changes from active disease into survivorship. This study involves wearing an activity monitor for 7 days, completing questionnaires, and one in-person study visit to UPMC Magee-Womens Hospital. Compensation is provided.
AtTACC Pain Study – Individuals with Ovarian Cancer
Do you have ovarian cancer? You may be able to participate in a study to help better understand how pain changes from active disease into survivorship. This study involves 3 sessions of wearing an activity monitor for 7 days, , completing questionnaires, and one two in-person study visit to UPMC Magee-Womens Hospital. Compensation is provided.
Memory and Attention Training for Individuals with Gastrointestinal Stromal Tumors (GIST)
Have you been diagnosed with a gastrointestinal stromal tumor (GIST)? Have you been taking a tyrosine kinase inhibitor therapy (Imatinib) for at least one year? You may be able to participate in a study to examine an intervention to treat changes in memory and concentration in people with GIST. Study participation involves completing an 8-week intervention using the computer and phone.
Telehealth and Memory Study
Are you a breast cancer survivor who completed chemotherapy one to five years ago? Do you have problems with your memory, concentration, and/or attention? You may be able to participate in a research study to test two treatments that may help breast cancer survivors improve cognitive function. This study involves 8 weeks of therapy completed online or by mobile phone, and optional MRI scanning.
Cancer and Cognition Research Study - GIST
Do you have a newly diagnosed gastrointestinal stromal tumor (GIST), but have not yet started treatment? If so, you may be able to participate in a research study to help learn more about possible changes in memory and concentration over time in people being treated for GIST. Participants will complete four assessments over one year via online surveys and telephone interviews.
iCARE Study – Parent or Grandparent Recently Diagnosed with Cancer
Have you recently been diagnosed with cancer? Are you the parent or grandparent of a child ages 10-17? If so, you and your child/grandchild may be able to participate in a research study to learn more about how stress from a parent or grandparent's cancer diagnosis affects children. Compensation provided.
HER2-Positive Breast Cancer with Brain Metastases: HCC 19-005 (TBCRC 022)
Do you have HER2-positive breast cancer that has spread to the brain? If so, you may be eligible to participate in a research study to help find out if an investigational combination of drugs called ado-trastuzumab emtansine (also known as T-DM1 or Kadcyla®) and neratinib (also known as Nerlynx®) is safe and effective for people with HER2-positive breast cancer that has spread to the brain.
HCC 18-087: Recurrent Ovarian Cancer Study
Do you have ovarian cancer that has recurred following treatment? If so, you may be eligible to participate in a research study to help find out if adding investigational drugs called pembrolizumab (Keytruda®) and rintatolimod (Ampligen®) to routine treatment with intraperitoneal cisplatin has an effect on recurrent ovarian cancer.
Have you been diagnosed with anaplastic lymphoma kinase positive (ALK+) non-small cell lung cancer? Has your doctor recommended that you start taking brigatinib (brand name Alunbrig) to treat your disease? If so, you may be eligible to participate in this study to help researchers study how often pulmonary (lung) issues such as breathing issues, pneumonia, etc. occur to patients taking brigatinib.
Have you been diagnosed with hormone receptor positive or triple negative breast cancer that is growing on your chest wall (chest wall disease)? If so, you may be eligible to participate in a study to help researchers see what effects, good or bad, the combination of pembrolizumab (KEYTRUDA) and carboplatin (chemotherapy) have on your cancer compared to carboplatin alone.
HCC-18-006 – Ovarian Cancer Study
Have you been diagnosed with ovarian cancer that has come back after your previous treatment? If so, you may be eligible to participate in a study to help investigators evaluate the safety of a new anticancer drug, called ribociclib (LEE011). Involves receiving the study drug along with chemotherapy for 24 weeks. You will then receive the study drug by itself (maintenance dose).
Do you have advanced stage non-small cell lung cancer (NSCLC) and have not previously been treated with other drugs? If so, you may be eligible to participate in a study to see if an investigational drug is safe, if it prevents your lung cancer from growing, and how long it works. Involves a screening period to see if you are eligible and up to 12 months of treatment.
Are you a woman age 40 or up who has been newly diagnosed (past 3 months) with non-invasive ductal carcinoma in situ (DCIS)? If so, you may be eligible for a study to help researchers evaluate the risks and benefits of usual treatment approach for DCIS vs. close monitoring approach. Study participation will last at least 5 years.
Endocrine Response in Women with Invasive Lobular Breast Cancer (ILC) (TBCRC 037)
Are you a postmenopausal woman with newly diagnosed invasive lobular breast cancer (ILC)? If so, you may be able to participate in a research study to learn more about how tumors respond to hormonal therapy in this population.